ESMO 2018: Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Category: Presentation
ASCO GU 2018: Tivozanib Combined With Nivolumab: Phase Ib/II Study in Metastatic Renal Cell Carcinoma
ASCO GU 2018: Tivozanib Combined With Nivolumab: Phase Ib/II Study in Metastatic Renal Cell Carcinoma
KCS 2017: TiNivo, A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma
KCS 2017: TiNivo, A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma
ASCO 2017: Phase I study of the anti-HGF monoclonal antibody, ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer
ASCO 2017: Phase I study of the anti-HGF monoclonal antibody, ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer
ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)
ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)
ASCO 2017: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
ASCO 2017: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
ASCO 2015: Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)
ASCO 2015: Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)
Annual Symposium on Anti-angiogenesis and Immune Therapies for Cancer 2015: Circulating neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib in metastatic clear cell renal cell carcinoma (RCC): post-hoc biomarker analysis of tivozanib RCC trials
Annual Symposium on Anti-angiogenesis and Immune Therapies for Cancer 2015: Circulating neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib in metastatic clear cell renal cell carcinoma (RCC): post-hoc biomarker analysis of tivozanib RCC trials
ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
ESMO 2014: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
ESMO 2014: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma